[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597071":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":19,"collaborators":10,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":27,"acronym":10,"eligibilityCriteria":28,"healthyVolunteers":25,"sex":29,"minAge":30,"maxAge":10,"enrollmentInfo":31,"targetDuration":34,"studyType":35,"phases":10,"briefSummary":36,"conditions":37,"keywords":39,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":10},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NA-TMT",null,"Patients with Muscle - Invasive Bladder Cancer Undergoing Bladder Preservation Therapy After Neoadjuvant Therapy",[13],"Radiation: NA-TMT",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"RADIATION","After neoadjuvant therapy, patients choose trimodality therapy (TMT) for bladder preservation over radical cystectomy.",[9],{"type":20,"investigatorFullName":21,"investigatorTitle":22,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Shangbin QIN","Doctor","100597071","observational-clinical-study-of-patients-with-muscle---invasive-bladder-cancer-undergoing-bladder-preservation-therapy-after-neoadjuvant-therapy-100597071",false,"NCT07053722","Observational Clinical Study of Patients With Muscle - Invasive Bladder Cancer Undergoing Bladder Preservation Therapy After Neoadjuvant Therapy","Inclusion Criteria:\n\nHistopathologically confirmed bladder cancer (T2-T4aN0-2M0, 8th edition AJCC staging).\n\nUnderwent bladder - sparing TMT following neoadjuvant therapy (ADC, immunotherapy, or chemotherapy).\n\nAged ≥18 years. Signed an informed consent form. Good general condition with ECOG performance status of 0-2. Adequate organ function for chemoradiotherapy: (1) Hematology: Absolute neutrophil count ≥1.5×10⁹\u002FL, platelets ≥100×10⁹\u002FL, hemoglobin ≥90 g\u002FL. (2) Liver function: Total bilirubin ≤1.5×ULN, ALT and AST ≤2.5×ULN (≤5×ULN if hepatic metastasis is present). (3) Renal function: Creatinine clearance ≥30 mL\u002Fmin (via Cockcroft-Gault formula).\n\nExclusion Criteria:\n\nDistant metastasis (M1). Other malignancies (except cured basal cell carcinoma or cervical carcinoma in situ).\n\nSevere cardiovascular disease (uncontrolled heart failure, unstable angina, myocardial infarction, etc.).\n\nSevere hepatic\u002Frenal dysfunction intolerance to chemoradiotherapy. Mental illness\u002Fcognitive impairment unable to comply with the study. Allergy to chemoradiotherapy drugs. Pregnant or breastfeeding women. Previous pelvic radiotherapy.","ALL","18 Years",{"count":32,"type":33},30,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational study is to evaluate the safety and efficacy of neoadjuvant therapy followed by bladder - preserving TMT in patients with MIBC. The main question it aims to answer is: Does this treatment model improve long - term outcomes, including survival, local control, distant metastasis, and bladder preservation rates? Participants who received neoadjuvant therapy and underwent TMT for bladder preservation will be observed.",[38],"Bladder (Urothelial, Transitional Cell) Cancer",[40,41,42],"radiation oncology","bladder cancer","TMT","NOT_YET_RECRUITING","2025-06-27",{"date":46,"type":47},"2025-07-08","ACTUAL",{"date":49,"type":33},"2025-06-30",{"date":51,"type":33},"2027-06-30",{"name":5,"class":6}]